Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy (RIC-NPDR): study protocol for a randomized controlled trial.
Xi-Zhe Wang, Shan He, Zhen Li...
https://pubmed.ncbi.nlm.nih.gov/41803826/Actively Recruiting
Led by Xuxiang Zhang, MD · Updated on 2025-06-26
68
Participants Needed
2
Research Sites
4 weeks
Total Duration
Researchers are evaluating remote ischemic conditioning RIC as a possible treatment for adults aged 40 to 80 years with mild to moderate non-proliferative diabetic retinopathy NPDR caused by type 2 diabetes. This study aims to see if RIC can improve the Diabetic Retinopathy Severity Score DRSS, reduce the risk of vision-threatening proliferative diabetic retinopathy PDR, and affect retinal and blood markers linked to eye health. NPDR is an early stage of diabetic retinopathy where current treatments have limitations, so this study tests a new, non-invasive approach. Participants will be randomly assigned to receive either RIC therapy or a placebo sham treatment using a specialized device. The RIC group will undergo five cycles of 5-minute arm cuff inflation at 200 mmHg followed by 5-minute deflation, done twice daily, five days per week for one year. The placebo group will have the same cycles but at a lower pressure of 60 mmHg to mimic the treatment without the active effect. Both groups will continue routine diabetic retinopathy care according to clinical guidelines. During the study, participants will have regular assessments of their eye health, including changes in DRSS, retinal nerve and blood vessel function, retinal oxygen levels, visual acuity, and blood tests for markers like VEGF, CRP, and IL-6. Safety and treatment effects will be monitored over the one-year treatment period. The study plans to recruit 68 participants to ensure enough data despite some expected dropouts and aims to provide early evidence on RICs potential for managing NPDR and preventing vision loss.
CONDITIONS
Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy
S
Shan He
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Xuxiang Zhang, MD
Lead Sponsor
Xuanwu Hospital, Beijing
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 year
Participants use a remote ischemic conditioning device or a sham device on both arms. This involves five cycles of 5-minute inflation and 5-minute deflation, twice daily, for at least five days per week over one year to evaluate effects on diabetic retinopathy.
Regular visits for assessments during treatment period
Duration - Assessment at 1 year after intervention
Participants undergo assessments to evaluate changes in diabetic retinopathy severity, retinal function, visual acuity, and serum biomarkers after the treatment period.
1 visit (in-person) at 1 year
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Xi-Zhe Wang, Shan He, Zhen Li...
https://pubmed.ncbi.nlm.nih.gov/41803826/Xuxiang Zhang, MD
Lead Sponsor
Xuanwu Hospital, Beijing
Collaborating Sponsor